Generic Rhofade Availability
Last updated on Apr 10, 2025.
Rhofade is a brand name of oxymetazoline topical, approved by the FDA in the following formulation(s):
RHOFADE (oxymetazoline hydrochloride - cream;topical)
-
Manufacturer: MAYNE PHARMA
Approval date: January 18, 2017
Strength(s): 1% [RLD]
Is there a generic version of Rhofade available?
No. There is currently no therapeutically equivalent version of Rhofade available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rhofade. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stabilized oxymetazoline formulations and their uses
Patent 10,335,391
Issued: July 2, 2019
Inventor(s): Sarpotdar Pramod & Warner Kevin & Zhang Steven & Ahluwalia Gurpreet & Kuang Amy
Assignee(s): ACLARIS THERAPEUTICS, INC.The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Patent expiration dates:
- June 11, 2035✓
- June 11, 2035
-
Stabilized oxymetazoline formulations and their uses
Patent 10,751,325
Issued: August 25, 2020
Inventor(s): Sarpotdar Pramod & Warner Kevin & Zhang Steven & Ahluwalia Gurpreet & Kuang Amy
Assignee(s): EPI HEALTH, LLCThe present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Patent expiration dates:
- June 11, 2035✓
- June 11, 2035
-
Stabilized oxymetazoline formulations and their uses
Patent 11,517,560
Issued: December 6, 2022
Inventor(s): Sarpotdar Pramod & Warner Kevin & Zhang Steven & Ahluwalia Gurpreet & Kuang Amy
Assignee(s): EPI HEALTH, LLCThe present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Patent expiration dates:
- June 11, 2035✓
- June 11, 2035
-
Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists
Patent 7,812,049
Issued: October 12, 2010
Inventor(s): Shanler; Stuart D. et al.
Assignee(s): Vicept Therapeutics, Inc. (Malvern, PA)The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .alpha..sub.1-adrenergic receptor (.alpha..sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
Patent expiration dates:
- May 2, 2028✓
- May 2, 2028
-
Pharmaceutical cream compositions and methods of use
Patent 8,883,838
Issued: November 11, 2014
Inventor(s): Shanler Stuart D. & Powala Christopher & Rios Luis
Assignee(s): Allergan, Inc.The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions.
Patent expiration dates:
- December 1, 2031✓
- December 1, 2031
-
Stabilized oxymetazoline formulations and their uses
Patent 9,974,773
Issued: May 22, 2018
Inventor(s): Sarpotdar Pramod & Warner Kevin & Zhang Steven & Ahluwalia Gurpreet & Kuang Amy
Assignee(s): Allergan, Inc.The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Patent expiration dates:
- June 11, 2035✓
- June 11, 2035
More about Rhofade (oxymetazoline topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (139)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical anti-rosacea agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.